Economic challenges associated with tuberculosis diagnostic development

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 4, 2014, Pages 499-510

  Hanrahan, Colleen F ^a   Shah, Maunank ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnostic development; Diagnostics; Economic evaluation; Tuberculosis; Tuberculosis control policy

Indexed keywords

LIPOARABINOMANNAN;

BACTERIUM CULTURE; CLINICAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ECONOMIC EVALUATION; EVALUATION RESEARCH; EXTRAPULMONARY TUBERCULOSIS; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE COST; HEALTH CARE PLANNING; HIV ASSOCIATED TUBERCULOSIS; HUMAN; LABORATORY DIAGNOSIS; LUNG TUBERCULOSIS; MILIARY TUBERCULOSIS; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PEDIATRIC TUBERCULOSIS; PROGRAM IMPACT; PUBLIC-PRIVATE PARTNERSHIP; RAPID TEST; REVIEW; SPUTUM CYTODIAGNOSIS; TB LIPOARABINOMANNAN; TUBERCULOSIS; ECONOMICS; HEALTH; HEALTH SERVICE; MANAGEMENT;

DIAGNOSTIC TESTS, ROUTINE; GLOBAL HEALTH; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; POLICY MAKING; TUBERCULOSIS;

EID: 84904313278     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.914438     Document Type: Review

References (80)

1. WHO. Global tuberculosis report. WHO; Geneva, Switzerland: 2013
2. World Bank. GDP (current US). 2012. Available from: Http://data. worldbank.org/ indicator/NY.GDP.MKTP.CD [Last accessed 7 January 2014]
3. Janssens JP, Rieder HL. An ecological analysis of incidence of tuberculosis. and per capita gross domestic product. Eur Respir J 2008;32:1415-16
4. Dorman SE. New diagnostic tests for tuberculosis: Bench, bedside, and beyond. Clin Infect Dis 2010;50(Suppl 3): S173-7
5. FIND & Special Programme for Tropical Disease Research and Training. Diagnostics for tuberculosis: Global demand and market potential. WHO; Geneva, Switzerland: 2006
6. Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: A modelbased analysis. AIDS 2012;26:987-95
7. Choi HW, Miele K, Dowdy D, Shah M. Cost-effectiveness of Xpert(R) MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis 2013;17:1328-35
8. Guerra RL, Dorman SE, Luiz RR, Conde MB. Cost-effectiveness of routine diagnostic evaluation of pulmonary tuberculosis in a primary care unit in Brazil. Int J Tuberc Lung Dis 2013;17:1336-40
9. Whitelaw A, Peter J, Sohn H, et al. Comparative cost and performance of light-emitting diode microscopy in HIV-Tuberculosis-co-infected patients. Eur Respir J 2011;38:1393-7
10. Davies PD, Pai M. The diagnosis and misdiagnosis of tuberculosis. Int J Tuberc Lung Dis 2008;12:1226-34
11. Diagnostic standards and classification of tuberculosis in adults and children. This official statement of the American thoracic society and the centers for disease control and prevention was adopted by the ATS Board of directors, July 1999. This statement was endorsed by the council of the infectious disease society of America, September 1999. Am J Respir Crit Care Med 2000;161: 1376-95
12. Shah M, Dowdy D, Joloba M, et al. Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda. AIDS 2013;27:2883-92
13. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: A cost-effectiveness analysis. PLoS Med 2011;8:e1001120
14. Pai NP, Pai M. Point-of-care diagnostics for HIV and tuberculosis: Landscape, pipeline, and unmet needs. Discov Med 2012;13: 35-45
15. UNITAID. Tuberculosis diagnostics technology landscape report. WHO; Geneva, Switzerland: 2012
16. Daniels C. The tuberculosis diagnostics pipeline. TAG HIV iBase. 2013. Available from: Www.pipelinereport.org/2013/tbdiagnostics [Last accessed 21 January 2014]
17. WHO. Automated real-Time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance; Xpert MTB/RIF system. WHO; Geneva, Switzerland: 2011
18. WHO. Frequently asked questions on Xpert MTB/RIF assay. WHO; Geneva, Switzerland: 2012. Available from: Www. who.int/tb/laboratory/xpert-faqs.pdf [Last accessed 15 January 2014]
19. van Zyl-Smit RN, Binder A, Meldau R, et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS One 2011;6: E28815
20. Steingart KR, Sohn H, Schiller I, et al. Xpert-MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013;1: CD009593
21. Ablanedo-Terrazas Y, Alvarado-de la Barrera C, Hernandez-Juan R, et al. Xpert MTB/RIF for diagnosis of tuberculous cervical lymphadenitis in HIV-infected patients. Laryngoscope 2013. [Epub ahead of print]
22. Banada PP, Koshy R, Alland D. Detection of Mycobacterium tuberculosis in blood by use of the Xpert MTB/RIF assay. J Clin Microbiol 2013;51:2317-22
23. Dhana AV, Howell P, Sanne I, Spencer D. Identification of Mycobacterium tuberculosis from pericardial fluid using the new Xpert MTB/RIF assay. BMJ Case Rep 2013 2013
24. Van Rie A, Page-Shipp L, Mellet K, et al. Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-Associated lymph node tuberculosis. Eur J Clin Microbiol Infect Dis 2013;32: 1409-15
25. Lawn SD, Nicol MP. Xpert-MTB/RIF assay: Development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011;6:1067-82
26. Pantoja A, Fitzpatrick C, Vassall A, et al. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: A cost and affordability analysis. Eur Respir J 2013;42:708-20
27. FIND. Negotiated prices for Xpert MTB/ RIF and FIND country list. 2013. Available from: Www.finddiagnostics.org/about/ what-we-do/successes/find- negotiatedprices/ xpert-mtb-rif.html [Last accessed 21 January 2014]
28. Schnippel K, Meyer-Rath G, Long L, et al. Scaling up Xpert MTB/RIF technology: The costs of laboratory-vs. clinic-based roll-out in South Africa. Trop Med Int Health 2012;17:1142-51
29. WHO. WHO monitoring of Xpert MTB/ RIF roll-out. 2013. Available from: Www. who.int/tb/laboratory/mtbrifrollout/en/ [Last accessed 20 January 2014]
30. Stevens W. GeneXpert implementation in South Africa public sectory: One year later: Lessons learnt. 4th WHO/GLI meeting. Veyrier-du-Lac, France; 2012
31. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-Associated tuberculosis: The epidemiology and the response. Clin Infect Dis 2010;50(Suppl 3): S201-7
32. WHO. World Tuberculosis Report Supplement: Countdown to 2015. WHO; Geneva, Switzerland: 2013
33. Dierberg KL, Chaisson RE. Human immunodeficiency virus-Associated tuberculosis: Update on prevention and treatment. Clin Chest Med 2013;34:217-28
34. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis 2010;14:1295-302
35. Harries AD, Maher D, Nunn P. An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa. Bull World Health Organ 1998;76:651-62
36. Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: The current evidence. Lancet Infect Dis 2003;3: 288-96
37. Naing C, Mak JW, Maung M, et al. Metaanalysis: The association between HIV infection and extrapulmonary tuberculosis. Lung 2013;191:27-34
38. Hargreaves NJ, Kadzakumanja O, Whitty CJ, et al 'Smear-negative' pulmonary tuberculosis in a DOTS programme: Poor outcomes in an area of high HIV seroprevalence. Int J Tuberc Lung Dis 2001;5:847-54
39. Harries AD, Hargreaves NJ, Gausi F, et al. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis 2001;5:1000-5
40. Martinson NA, Karstaedt A, Venter WD, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: An autopsy study. AIDS 2007;21:2043-50
41. Cox JA, Lukande RL, Nelson AM, et al. An autopsy study describing causes of death and comparing clinico-pathological findings among hospitalized patients in Kampala, Uganda. PLoS One 2012;7:e33685
42. Peto HM, Pratt RH, Harrington TA, et al. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis 2009;49: 1350-7
43. Houston A, Macallan D. Extrapulmonary tuberculosis. Medicine 2014;42:18-22
44. Golden MP, Vikram HR. Extrapulmonary tuberculosis: An overview. Am Fam Physician 2005;72:1761-8
45. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-Associated pulmonary tuberculosis before antiretroviral therapy: A descriptive study. Lancet Infect Dis 2012;12:201-9
46. Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-Test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012;40:1211-20
47. Lawn SD, Kerkhoff AD, Vogt M, Wood R. HIV-Associated tuberculosis: Relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays. BMC Med 2013;11:231
48. Sun D, Dorman S, Shah M, et al. Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults. Int J Tuberc Lung Dis 2013;17:552-8
49. Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med 2012;367:348-61
50. Marais BJ, Hesseling AC, Gie RP, et al. The bacteriologic yield in children with intrathoracic tuberculosis. Clin Infect Dis 2006;42:e69-71
51. Zar HJ, Hanslo D, Apolles P, et al. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: A prospective study. Lancet 2005;365:130-4
52. Graham SM, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012; 205(Suppl 2):S199-208
53. STOP TB Partnership. New Diagnostics Working Group. 2013. Available from: Www.stoptb.org/wg/new-diagnostics/default. asp [Last accessed 22 January 2014]
54. Stop TB Partnership, Diagnostic Working Group. Pathways to better diagnostics for tuberculosis: A blueprint for the development of TB diagnostics. WHO; Geneva, Switzerland: 2009
55. Tebbey PW, Rink C. Target product profile: A renaissance for its definition and use. J Med Mark 2009;9:301-7
56. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 2009;7: 845-55
57. Pai M. Answers to target product profiles. 2013. Available from: Www.tbfaqs.org/targetproduct-profiles/answers-To-Target-productprofiles/[Last] [accessed 26 January 2014]
58. WHO. WHO warns against the use of inaccurate blood tests for active tuberculosis. WHO; Geneva, Switzerland: 2011
59. Steingart KR, Flores LL, Dendukuri N, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: An updated systematic review and meta-Analysis. PLoS Med 2011;8:e1001062
60. WHO. WHO warns against the use of inaccurate blood tests for active tuberculosis. 2011. Available from: Www.who.int/ mediacentre/news/releases/2011/ tb-20110720/en/ [Last accessed 15 January 2014]
61. Frick M, Jimenez-Levi E. Report on tuberculosis research funding trends, 2005-2012. Treatment Action Group Stop TB Partnership. New York, NY, USA; 2013
62. Diaceutics. Mystery solved! What is the cost to develop and launch a diagnostic? 2013. Available from: Www.diaceutics.com/ mystery-solved-what-cost- develop-Andlaunch-diagnostic [Last accessed 28 January 2014]
63. STOP TB Partnership. TB Strain Bank. Available from: Www.stoptb.org/wg/ new-diagnostics/strainbank.asp [Last accessed 28 January 2014]
64. FIND. Tuberculosis specimen bank. Available from: Www.finddiagnostics. org/ programs/tb/find-Activities/ tb-specimen-bank.html [Last accessed 28 January 2014]
65. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-15
66. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet 2011;377:1495-505
67. Lawn SD, Kerkhoff AD, Burton R, et al. Massive diagnostic yield of HIV-Associated tuberculosis using rapid urine assays in South Africa. Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA;2014
68. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med 2003;138:40-4
69. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edition. Oxford University Press; Oxford, UK: 2005
70. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low-And middle-income countries: A review of the debates surrounding decision rules. Pharmacoeconomics 2009;27:903-17
71. Hanrahan CF, Dorman SE, Erasmus L, et al. The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: An observational cohort study. PLoS One 2012;7:e49898
72. Andrews JR, Lawn SD, Dowdy DW, Walensky RP. Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-Associated tuberculosis. Clin Infect Dis 2013;57:1021-6
73. Hygiene Maryland Dept of Health and Mental Hygeine. Maryland TB guidelines for prevention and treatment of tuberculosis. Maryland Department of Health and Mental Hygiene; Baltimore, MD: 2007
74. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: A systematic review and meta-Analysis. BMC Infect Dis 2005;5:62
75. WHO. Molecular line probe assays for rapid screening of patients at risk of multidrug resistant tuberculosis. Geneva, Switzerland: 2008
76. NHLS. NPP implementation of GeneXpert for TB testing. Available from: Www.nhls.ac. za/?page=genexpert-for-Tb-Testing&id=69[Last accessed 28 January 2014]
77. Cobelens F, van den Hof S, Pai M, et al. Which new diagnostics for tuberculosis, and when? J Infect Dis 2012;205(Suppl 2): S191-8
78. WHO. Rapid implementation of the Xpert MTB/RIF diagnostic test. Geneva, Switzerland: 2011
79. Lawn SD, Dheda K, Kerkhoff AD, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-Associated tuberculosis: Recommendations on the design and reporting of clinical studies. BMC Infect Dis 2013;13:407
80. STOP TB Partnership. New diagnostics working group. Available from: Http://www. stoptb.org/wg/new-diagnostics/default.asp [Last accessed 28 January 2014].